Secondary effects and biochemical control in patients with early prostate cancer treated with (125)-I seeds.
OBJECTIVE
To retrospectively evaluate the toxicity of low-dose-rate brachytherapy and to relate it to the dose-volume to organs at risk.


METHODS
We study 160 patients with early prostate cancer, treated with (125)-I implants. Most of them were T1c (63.1%), T2a (35.6%) and Gleason < or =6 (96.2%). Median PSA was 7.2 ng/ml (2.3-13.5); 85.6% were lowrisk cases and 14.4% high-risk cases. Mean follow-up was 24 months (7-48).


RESULTS
Acute urinary toxicity related to urological quality of life (UQL=CVU) was tolerable in 75% and unsatisfactory in 25%. Urinary retention was present in 6.9%. IPSS, V100 and D90 were related to the urinary toxicity grade. Rectal toxicity (RTOG) G2 was 0.6%. Sexual potency showed no changes with regard to the basal in 69%. Actuarial biochemical control was 89.8% at four years.


CONCLUSIONS
Brachytherapy with (125)-I seeds yields acceptable toxicity and excellent biochemical control.
Radiation Oncology Department, F. Instituto Valenciano de Oncología, Valencia, Spain.
V
V
Morillo
J L
JL
Guinot
I
I
Tortajada
J V
JV
Ricós
L
L
Arribas
M
M
Maroñas
M
M
Estornell
J
J
Casanova
D000368:Aged; D001918:Brachytherapy / Q000009:adverse effects*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood / Q000528:radiation effects*; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011788:Quality of Life; D012189:Retrospective Studies; D012735:Sexual Dysfunction, Physiological / Q000453:epidemiology / Q000209:etiology; D014551:Urinary Tract / Q000528:radiation effects; D014555:Urination Disorders / Q000453:epidemiology / Q000209:etiology*
D007457:Iodine Radioisotopes; D017430:Prostate-Specific Antigen